Experimental and Clinical Pharmacopsychology, Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatric Hospital of the University of Zurich, Lenggstrasse 31, 8032 Zurich, Switzerland.
Experimental and Clinical Pharmacopsychology, Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatric Hospital of the University of Zurich, Lenggstrasse 31, 8032 Zurich, Switzerland.
Eur Neuropsychopharmacol. 2017 Oct;27(10):987-999. doi: 10.1016/j.euroneuro.2017.08.425. Epub 2017 Aug 31.
Chronic use of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") has repeatedly been associated with deficits in working memory, declarative memory, and executive functions. However, previous findings regarding working memory and executive function are inconclusive yet, as in most studies concomitant stimulant use, which is known to affect these functions, was not adequately controlled for. Therefore, we compared the cognitive performance of 26 stimulant-free and largely pure (primary) MDMA users, 25 stimulant-using polydrug MDMA users, and 56 MDMA/stimulant-naïve controls by applying a comprehensive neuropsychological test battery. Neuropsychological tests were grouped into four cognitive domains. Recent drug use was objectively quantified by 6-month hair analyses on 17 substances and metabolites. Considerably lower mean hair concentrations of stimulants (amphetamine, methamphetamine, methylphenidate, cocaine), opioids (morphine, methadone, codeine), and hallucinogens (ketamine, 2C-B) were detected in primary compared to polydrug users, while both user groups did not differ in their MDMA hair concentration. Cohen's d effect sizes for both comparisons, i.e., primary MDMA users vs. controls and polydrug MDMA users vs. controls, were highest for declarative memory (d=.90, d=1.21), followed by working memory (d=.52, d=.96), executive functions (d=.46, d=.86), and attention (d=.23, d=.70). Thus, primary MDMA users showed strong and relatively discrete declarative memory impairments, whereas MDMA polydrug users displayed broad and unspecific cognitive impairments. Consequently, even largely pure chronic MDMA use is associated with decreased performance in declarative memory, while additional deficits in working memory and executive functions displayed by polydrug MDMA users are likely driven by stimulant co-use.
慢性使用 3,4-亚甲二氧基甲基苯丙胺(MDMA,“摇头丸”)与工作记忆、陈述性记忆和执行功能缺陷反复相关。然而,由于大多数研究没有充分控制伴随的兴奋剂使用,而兴奋剂使用已知会影响这些功能,因此之前关于工作记忆和执行功能的研究结果尚无定论。因此,我们通过应用综合神经心理学测试组合,比较了 26 名无兴奋剂且主要为纯(原发性)MDMA 用户、25 名使用兴奋剂的多药 MDMA 用户和 56 名 MDMA/兴奋剂未使用者的认知表现。神经心理学测试分为四个认知领域。最近的药物使用通过对 17 种物质和代谢物的 6 个月毛发分析进行客观量化。与多药使用者相比,原发性 MDMA 用户的兴奋剂(安非他命、甲基苯丙胺、哌醋甲酯、可卡因)、阿片类药物(吗啡、美沙酮、可待因)和致幻剂(氯胺酮、2C-B)的平均毛发浓度明显较低,而这两个使用者群体在 MDMA 毛发浓度方面没有差异。这两个比较的 Cohen's d 效应大小,即原发性 MDMA 用户与对照组和多药 MDMA 用户与对照组,最高的是陈述性记忆(d=.90,d=1.21),其次是工作记忆(d=.52,d=.96),执行功能(d=.46,d=.86)和注意力(d=.23,d=.70)。因此,原发性 MDMA 用户表现出强烈且相对离散的陈述性记忆损伤,而 MDMA 多药使用者表现出广泛且非特异性的认知损伤。因此,即使是大量纯慢性 MDMA 使用也与陈述性记忆表现下降相关,而多药 MDMA 用户显示的工作记忆和执行功能额外缺陷可能是由兴奋剂共同使用驱动的。